Administrative Core
行政核心
基本信息
- 批准号:10625687
- 负责人:
- 金额:$ 5.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-03 至 2028-02-29
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAntibodiesAntigensClostridium difficileCommunitiesComplexDataEnsureFeedbackFosteringGoalsHuman ResourcesInstitutionIntellectual PropertyLeadershipLinkMonitorMucosal ImmunityNational Institute of Allergy and Infectious DiseaseNotificationProductivityReagentReportingResearchResearch PersonnelResourcesScienceTechnology TransferTravelUnited States National Institutes of HealthVaccinescommercializationenteric infectionexperienceimprovedmeetingsmemberprogramspublic databasesuccess
项目摘要
ADMINISTRATIVE CORE PROJECT SUMMARY
The Administrative Core for the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile
Vaccines (VANDy-CdV) program will serve to integrate and facilitate the broad range of activities that will be
undertaken within the program. This core will benefit from considerable administrative leadership experience
among the team members as well as strong institutional support. Four specific aims/responsibilities are
proposed. The first aim will be to coordinate program activities. The success of VANDy-CdV will depend on
frequent and meaningful interactions between all investigators. A Local Steering Committee composed of project
leaders, core directors, and key personnel will meet monthly to monitor progress, guide scientific directions, and
to monitor finance- and compliance-related issues. In addition, a full team meeting will occur quarterly to foster
productive and collaborative research. All VANDy-CdV members will be invited to share progress and solicit
constructive feedback. The Administrative Core will plan, coordinate, and document the activities from these
meetings. The second aim will be to interface with NIAID Program Officers and ensure that NIH reporting
requirements are met. In addition to official reporting requirements, the Administrative Core will notify the NIH of
all VANDy-CdV monthly and quarterly meetings. The Core will generate reports following each meeting and
distribute these reports to Local Steering Committee leaders and NIAID Program Officers. The Administrative
Core will also coordinate travel for VANDy-CdV members to attend and participate in Annual Programmatic
Meetings. The third aim is to provide fiscal oversight. Vanderbilt University Medical Center is ultimately
responsible for all spending decisions involving VANDy-CdV; however, the initial level of fiscal oversight will be
the responsibility of the Administrative Core. The fourth aim is to manage intellectual property, resource and
reagent distribution, and transmittal of data to public databases. Opportunities relating to intellectual property
across the projects and cores will be handled by the Administrative Core in conjunction with the Vanderbilt Center
for Commercialization and Technology Transfer (CTTC). The Administrative Core also will ensure that all
reasonable requests for reagents from any VANDy-CdV program are satisfied within a timely manner.
行政核心项目摘要
范德比尔特艰难梭菌抗体和抗原发现的管理核心
疫苗(VANDy-CdV)计划将有助于整合和促进广泛的活动,这些活动将
计划内进行。该核心将受益于丰富的行政领导经验
团队成员之间以及强大的机构支持。四个具体目标/责任是
建议的。第一个目标是协调计划活动。 VANDy-CdV 的成功将取决于
所有调查人员之间进行频繁且有意义的互动。地方指导委员会由项目组成
领导者、核心董事和关键人员每月举行一次会议,监测进展情况,指导科学方向,并
监控财务和合规相关问题。此外,每季度将召开一次完整的团队会议,以促进
富有成效的协作研究。所有 VANDy-CdV 成员将被邀请分享进展并征求意见
建设性的反馈。行政核心将计划、协调和记录这些活动
会议。第二个目标是与 NIAID 项目官员进行沟通,并确保 NIH 报告
满足要求。除了官方报告要求外,行政核心还将通知 NIH:
所有 VANDy-CdV 月度和季度会议。核心将在每次会议后生成报告
将这些报告分发给地方指导委员会领导人和 NIAID 项目官员。行政部门
Core 还将协调 VANDy-CdV 成员参加年度计划的旅行
会议。第三个目标是提供财政监督。范德比尔特大学医学中心最终
负责涉及 VANDy-CdV 的所有支出决策;然而,财政监督的初始水平将是
行政核心的职责。第四个目标是管理知识产权、资源和
试剂分配以及将数据传输到公共数据库。与知识产权相关的机会
跨项目和核心的事务将由行政核心与范德比尔特中心一起处理
商业化和技术转让(CTTC)。行政核心还将确保所有
及时满足任何 VANDy-CdV 计划对试剂的合理要求。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dana Borden Lacy其他文献
Dana Borden Lacy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dana Borden Lacy', 18)}}的其他基金
Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines
艰难梭菌疫苗的范德比尔特抗体和抗原发现
- 批准号:
10625686 - 财政年份:2023
- 资助金额:
$ 5.23万 - 项目类别:
Project 1: Mucosal toxin subunit immunization as a strategy for C. difficile vaccine development
项目 1:粘膜毒素亚基免疫作为艰难梭菌疫苗开发的策略
- 批准号:
10625692 - 财政年份:2023
- 资助金额:
$ 5.23万 - 项目类别:
12th International Conference on the Molecular Biology and Pathogenesis of Clostridia (Clostpath 12)
第十二届梭状芽胞杆菌分子生物学和发病机制国际会议 (Clostridia 12)
- 批准号:
10318438 - 财政年份:2021
- 资助金额:
$ 5.23万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
10412917 - 财政年份:2015
- 资助金额:
$ 5.23万 - 项目类别:
Pre-clinical evaluation of Clostridium difficile toxin inhibitors
艰难梭菌毒素抑制剂的临床前评价
- 批准号:
9487905 - 财政年份:2015
- 资助金额:
$ 5.23万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
9889242 - 财政年份:2015
- 资助金额:
$ 5.23万 - 项目类别:
The role of toxins in Clostridium difficile infection pathogenesis
毒素在艰难梭菌感染发病机制中的作用
- 批准号:
10516088 - 财政年份:2015
- 资助金额:
$ 5.23万 - 项目类别:
Structural mechanisms of Clostridium difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
9212765 - 财政年份:2011
- 资助金额:
$ 5.23万 - 项目类别:
Structural Mechanisms of Clostridioides difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
10620653 - 财政年份:2011
- 资助金额:
$ 5.23万 - 项目类别:
Structural mechanisms of Clostridium difficile pathogenesis
艰难梭菌发病机制的结构机制
- 批准号:
9916698 - 财政年份:2011
- 资助金额:
$ 5.23万 - 项目类别:
相似国自然基金
原位疫苗新策略:抗体偶联仿生ROS纳米酶增强巨噬细胞吞噬及抗原交叉呈递效应
- 批准号:32371454
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
抗变构/单体形式的C反应蛋白关键抗原表位199-206抗体在狼疮性肾炎小管间质病变中的作用机制及其靶向治疗研究
- 批准号:82300829
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
靶向CLDN18.2抗体的抗原结合特性对CAR-T抗肿瘤活性的调控机制
- 批准号:82303716
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于抗原抗体相互作用的抗体定向虚拟设计与筛选
- 批准号:32370697
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
CD40-CD154共刺激信号介导的TD/TI抗原诱导罗非鱼抗体分泌细胞形成机制的比较研究
- 批准号:32303044
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of Coccidioides Cytokine Release Assay
球孢子菌细胞因子释放测定的发展
- 批准号:
10760131 - 财政年份:2023
- 资助金额:
$ 5.23万 - 项目类别:
CORE 1: The Clinical Data and Biospecimen Repository Core
核心 1:临床数据和生物样本存储库核心
- 批准号:
10625688 - 财政年份:2023
- 资助金额:
$ 5.23万 - 项目类别:
High-throughput immunoproteomics for cancer biomarker discovery
用于癌症生物标志物发现的高通量免疫蛋白质组学
- 批准号:
10688268 - 财政年份:2022
- 资助金额:
$ 5.23万 - 项目类别: